News

Illumina Inc. has recently forged a partnership with Janssen Research & Development, LLC to advance the development of Illumina's unique molecular residual disease assay.

Omniose, a preclinical biotechnology company, has recently revealed an exclusive collaboration agreement with AstraZeneca to investigate potential vaccines

Turbine, a notable biological simulation company specializing in the creation of a platform for simulating human biology in silico, has recently disclosed a collaboration with AstraZeneca, a global biopharmaceutical company

Merck, a prominent science and technology company, has recently entered into a licensing agreement with Inspirna, Inc. based in New York, NY, for ompenaclid, an innovative oral inhibitor targeting

INOVIO, a biotechnology company specializing in DNA medicines for HPV-associated diseases, cancer, and infectious diseases, recently disclosed a clinical collaboration and supply agreement with Coherus BioSciences.

AC Immune SA has released a positive update on its active immunotherapy programs, revealing that three Phase 2 trials are advancing towards significant clinical milestones in 2024. Dr. Andrea Pfeifer,

Elektrofi, Inc., a company specializing in biopharmaceutical formulation technology, has recently unveiled a global research collaboration and licensing agreement with Janssen Biotech, Inc., a subsidiary of Johnson & Johnson

Avenue Therapeutics, Inc, a specialized pharmaceutical company dedicated to advancing therapies for neurologic diseases, has successfully enrolled all participants in the Phase 1b/2a clinical trial of AJ201

Windtree Therapeutics, Inc, a biotechnology company specializing in advanced interventions for critical cardiovascular disorders, has announced novel preclinical data on its lead product candidate, istaroxime,

ANGLE plc, a prominent player in liquid biopsy technology focused on circulating tumor cell diagnostics for research, drug development, and clinical oncology, has recently entered into a noteworthy agreement with Eisai Inc